Adial Pharmaceuticals (ADIL) Net Equity Issued and Repurchased (2019 - 2026)

Adial Pharmaceuticals has reported Net Equity Issued and Repurchased for 7 years, with the latest figure at $315284.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased rose 522.5% year-over-year to $315284.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 57.19% YoY) and the FY2025 annual result came in at $3.7 million, down 9.02% from the prior year.
• Net Equity Issued and Repurchased eased to $315284.0 in Q1 2026 per ADIL's latest filing, from $3.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $9.1 million in Q1 2022 and troughed at -$3.6 million in Q2 2024.
• A 5-year average of $2.1 million and a median of $1.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased jumped 2765.73% in 2024, then plunged 98.73% in 2025.
• Over 5 years, Net Equity Issued and Repurchased stood at $9.1 million in 2022, then plunged by 98.46% to $140330.0 in 2023, then surged by 2765.73% to $4.0 million in 2024, then slipped by 10.36% to $3.6 million in 2025, then tumbled by 91.25% to $315284.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $315284.0, $3.6 million, and $3.1 million for Q1 2026, Q3 2025, and Q2 2025 respectively.